Continuous Intravenous Inotropes in Ward Units: Expanding Therapy Outside Intensive
            Care using a Safety-Oriented Protocol

Hastenteufel, Laura Caroline Tavares; Clausell, Nadine Oliveira; Neyeloff, Jeruza Lavanholi; Domingues, Fernanda Bandeira; Caballero, Larissa Gussatschenko; Silva, Eneida Rejane Rabelo da; Goldraich, Lívia Adams

doi:10.5935/abc.20190078

Cited by 1 publication

(1 citation statement)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role and safety of low‐to‐moderate doses of IV inotropic agents were described also in the experience of Hastenteufel et al ., 9 in which they described a safety‐focused protocol for hospitalized advanced HF patients outside the intensive care unit. As in our experience, the positive effect was correlated with use of low‐to‐moderate doses of IV inotropic, with a median dose of dobutamine and milrinone in their patients of respectively 5.7 and 0.25 mcg/kg/min.…”

Section: Discussionmentioning

confidence: 99%

Long‐term administration of intravenous inotropes in advanced heart failure

et al. 2021

View full text Add to dashboard Cite

Background Patients in heart transplantation (HTx) waiting list for advanced heart failure (HF) are susceptible to acute deterioration refractory to standard HF medical therapies. Limited data are available on long-term in-hospital continuous intravenous (IV) inotropic therapy as bridge to definite therapies. Methods and results Wereviewed medicalrecordsofallhearttransplantrecipientstreatedinthepre-HTx phase with in-hospital continuous IV inotropes at our institution between 2012 and 2018. We analysed data before the beginning of continuous IV therapy and at the moment of HTx. We report data of 24 patients (mean age of 43.5 ± 15.7 years) treated with IV inotropes as bridge to HTx (median follow-up of 28 months after HTx). The main length of IV inotropic therapy was 84 ± 66 days (min 22; max 264 days). At the beginning, the most frequently used inotrope was dopamine (median dosage of 3 mcg/kg/min, interquartile range 2.5-3.75), alone (n = 11, 46%) or in combination with other inotropes (n = 13, 54%). In 18 patients, the class of inotropes was changed during the hospitalization. We registered a progressive improvement of perfusion markers and neuro-hormonal activation. Conclusion In-hospital continuous parenteral inotropic therapy may serve as a temporary pharmacological bridge to HTx in patients with advanced HF that are actively listed to HTx with good reply in terms of prognosis and perfusion markers.

show abstract

Section: Discussionmentioning

confidence: 99%